![](/_upload/article/images/2e/c3/875fb6314a0d8f911afe2fb2bf7b/cbe4e979-9e0a-4e05-a059-66b821deb7e2.jpg)
张舰
生物工程专业:硕士生导师
生物与医药专业(生物工程领域):硕士生导师
张舰,工学博士,副教授,硕士生导师。2015年毕业于suncitygroup太阳新城获生物化工专业工学博士学位,同年进入suncitygroup太阳新城化学工程与技术流动站从事博士后研究工作,2018年3月出站担任教职。
近年来,依托生物反应器工程国家重点实验室和鲁华生物技术研究所,在重组抗肿瘤蛋白药物的制备及其活性研究方面开展了系统性研究工作。作为项目负责人主持国家自然科学青年基金、国家重点研发计划子课题、上海市自然科学基金、中国博士后基金面上项目、中央高校基本科研业务项目等,主持和参与多项企业横向课题。在Journal of Cellular Physiology, ACS Synthetic Biology, Molecular Pharmaceutics, Scientific Reports, Applied Microbiology and Biotechnology等本领域重点期刊上发表SCI收录论文二十余篇,申请PCT专利1项,中国发明专利5项。指导本科生承担国家/上海市级“大学生创新创业训练计划”2项。作为主要完成人获得2022年上海市科技进步一等奖。
研究方向:
1. 重组蛋白药物制备
针对重组蛋白药物生产及应用中的关键问题,利用微生物代谢工程和合成生物学的最新技术对生产宿主和表达载体进行改造,开发高效能生产菌株;
2. 重组蛋白药物活性改造
采用理性设计方法进行药物结构改造,提高抗肿瘤药物靶向性;结合药物作用机理,实现抗肿瘤药物活性的变构调控,降低药物毒副作用,推进候选药物分子的临床前及临床研究。
3. 生物过程智能优化与调控
基于多组学大数据及微生物代谢模型,对蛋白药物和生物基化学品生产菌株的发酵过程进行智能优化与调控,建立多种宿主的发酵新工艺,实现从实验室小试优化到工厂中试以及工业化生产的一体化体系。
主持或参加的科研项目
1. 上海市自然科学基金项目(22ZR1418300),2022/4-2025/3,20万元,主持
2. 国家自然科学基金青年基金项目(21706072),2018/1-2020/12,24万元,主持
3. 国家自然科学基金应急管理项目(21646005),2017/1-2017/12,10万元,主持
4. 国家重点研发计划子课题(2022YFA0912204),2022/11-2027/10,60万元,主持
5. 中国博士后科学基金面上项目(2016M601529),2016/09-2018/09,5万元,主持
6. 中央高校基本科研业务费(222201414019),2014/08-2016/08,10万元,主持
7. 国家自然科学基金面上项目(21778018),2018/1-2021/12,60万元,参与
8. 企业横向课题,HIV疫苗的发酵、纯化工艺开发,2016/01-2016/12,20万元,主持
9. 企业横向课题,新冠病毒诊断用酶制备工艺开发,2021/01-2023/12,50万元,主持
教学:
1. 本科生专业选修课,《分子病理学》,32学时,2学分;
2. 本科生全校公选课,《肿瘤生物学导论》,32学时,2学分;
代表性论文(*通讯作者, #共同第一):
1. Min Wei, Anxiang Chen, Jian Zhang*, Yuhong Ren*. A novel oxygen-dependent degradable immunotoxin regulated by ubiquitin-proteasome system reduces non-specific cytotoxicity. Molecular Pharmaceutics. 2023, 20(1):90-100
2. Yuting Li, Ming Zhao, Dongzhi Wei, Jian Zhang*, Yuhong Ren*. Photocontrol of itaconic acid synthesis in Escherichia coli. ACS Synthetic Biology. 2022, 11(6):2080-8
3. Yingjie Han, Xiaomei Zhu, Xuedong Wang*, Jian Zhang*. Oxygen bioavailability is a rate‑limited factor in phytosterols bioconversion using a cyclodextrin‑resting cell system. Catalysis Letters. 2022, doi:10.1007/s10562-022-04090-4
4. Jian Zhang*, Wanyuan Dong, Yuhong Ren, Dongzhi Wei. SAC‑TRAIL, a novel anticancer fusion protein: expression, purification, and functional characterization. Applied Microbiology and Biotechnology. 2022, 106(4):1511-20
5. Jian Zhang*, Kaizheng Zhang, Yuhong Ren, Dongzhi Wei. The expression, purification, and functional evaluation of the novel tumor suppressor fusion protein IL‑24‑CN. Applied Microbiology and Biotechnology. 2021, 105(20):7889-98
6. Da Wang#, Jian Zhang#, Dan-Dan Cao, Xuedong Wang*, Dongzhi Wei. Identification and in situ removal of an inhibitory intermediate to develop an efficient phytosterol bioconversion process using a cyclodextrin-resting cell system. RSC Advances. 2021, 11, 24787-93
7. Zhaoyu Chang#, Jian Zhang#, Wanyuan Dong, Xiangqi Meng, Hualei Wang, Dongzhi Wei, Yuhong Ren*. Cadmium sulfide net framework nanoparticles for photo-catalyzed cell redox. RSC Advances. 2020, 10, 37820-5
8. Zhong Wang, Jian Zhang*, Xuedong Wang*, Dongzhi Wei. High level expression and characterization of the recombinant immunotoxin DAB389-4D5 scFv targeting HER2/neu-positive ovarian carcinoma cells. Process Biochemistry. 2019, 80:26-34
9. Pengyan Jiao, Jian Zhang*, Yuguo Dong, Dongzhi Wei, Yuhong Ren*. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum. Applied Microbiology and Biotechnology. 2018, 102:9585-94
10. Jian Zhang*, Aiyou Sun*, Yuguo Dong, Dongzhi Wei. Recombinant production and characterization of SAC, the core domain of Par-4, by SUMO fusion system. Applied Biochemistry and Biotechnology. 2018, 184:1155-67
11. Jian Zhang, Rui Xu, Xinyi Tao, Yuguo Dong, Xinxin Lv, Aiyou Sun*, Dongzhi Wei*. TAT-IL-24-KDEL-induced apoptosis is inhibited by survivin but restored by the small molecular survivin inhibitor, YM155, in cancer cells. Oncotarget. 2016, 7:37030-42
12. Jian Zhang, Aiyou Sun*, Rui Xu, Xinyi Tao, Yuguo Dong, Xinxin Lv, Dongzhi Wei*. Cell-penetrating and endoplasmic reticulum-locating TAT-IL-24-KDEL fusion protein induces tumor apoptosis. Journal of Cellular Physiology. 2016, 231:84-93
13. Xinxin Lv#, Jian Zhang#, Rui Xu, Yuguo Dong, Aiyou Sun*, Yaling Shen, Dongzhi Wei*. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells. Applied Microbiology and Biotechnology. 2016, 100:6403-13
14. Jian Zhang, Xinxin Lv, Rui Xu, Xinyi Tao, Yuguo Dong, Aiyou Sun*, Dongzhi Wei*. Soluble expression, rapid purification and characterization of human interleukin-24 (IL-24) using a MBP-SUMO dual fusion system in Escherichia coli. Applied Microbiology and Biotechnology. 2015, 99:6705-13
发明专利:
1. Aiyou Sun, Dongzhi Wei, Jian Zhang, Xiaojuan Wang, Chaogang Bai, Rui Xu, Yuguo Dong, Xing Zhang. The preparation and application of fusion protein TAT-IL-24-KDEL. PCT/CN2014/087669
2. 张舰,任宇红,魏东芝,董万元.一种SAC-TRAIL融合蛋白及其制备方法和应用.申请号202110836049.0
3. 孙爱友,魏东芝,张舰,王晓娟,白超刚,徐瑞,董玉国,张星.TAT-IL-24-KDEL融合蛋白及其制备方法和应用.专利号ZL201410016426.6
联系方式:
上海市徐汇区梅陇路130号邮编200237
办公室:实验十四楼鲁华生物技术研究所302室
电话:021-64253715
邮箱:zhangjian0020@ecust.edu.cn